Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests
Information source: Ohio State University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Allergic Rhinitis
Intervention: saline with 1mg/ml Histamine base (Drug); diluent, saline with HSA--phenol (Drug)
Phase: Phase 1/Phase 2
Status: Recruiting
Sponsored by: Bryan Martin, DO Official(s) and/or principal investigator(s): Bryan Martin, DO, Principal Investigator, Affiliation: Ohio State University
Overall contact: Bryan Martin, DO, Phone: 614-2934975, Email: bryan.martin@osumc.edu
Summary
This is a double-blind study with respect to the diluents used, with patients known to be
allergic to the specific allergen tested. Three study sites will be involved, each testing
one allergen (Cat, Mite, Timothy grass pollen). Subjects who are known to be allergic to
the allergen in question will be tested with serial three-fold dilutions to determine the ID
50 and relative extract potency using the method described by Turkeltaub.
Clinical Details
Official title: Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests
Study design: Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)
Primary outcome: to determine the stability of immunotherapy extract dilutions
Detailed description:
The specific objective of this study is to determine the stability of immunotherapy extract
dilutions. Higher dilutions (lower potency) have been shown in vitro to decrease in potency
over time more rapidly than less dilute preparations. The investigators hope to determine
whether there is a detectable difference in skin test reaction of dilutions of three common
antigens (Cat, Timothy Grass, Dust Mite). The diluents used strongly affect the strength
when extract potency is tested in vitro. Therefore, the investigators expect to find a
detectable difference in skin test potency based on the diluents used (Saline vs. HSA Saline
[300mcg/ml]).
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 1. Subjects must demonstrate their willingness to participate in the study and comply
with its procedures by signing a written informed consent.
2. Subjects of either gender, ages 18-60 years, with a history of allergic rhinitis
related to exposure to the allergen of interest.
3. Previous positive routine skin test to the allergen to be tested: minimum 5mm
wheal diameter with 10,000BAU/mL cat or minimum 5mm wheal diameter with 10,000AU/mL
Dermatophagoides farinae or minimum 8mm wheal diameter with timothy 100,000BAU/mL.
4. AND (in addition to #3) sum of erythema after SPT of at least 50mm or erythema in
largest diameter of at least 30mm.
5. Subject's skin coloring should permit evaluation of erythema. 6. Ability to stop
medication that might interfere with the results of the skin prick test.
Exclusion Criteria:
- 1. Spirometry with FEV1 below 80% of predicted normal value and/or poorly controlled
asthma 2. Known pregnancy 3. Patients with a history of anaphylaxis or severe allergic
reactions. 4. Patients with absolute necessity of antihistamines to control their
allergies 5. Patients with active and extensive atopic dermatitis. 6. Patients that take
psychotropic medication. 7. General skin hyperreactivity (Negative control greater than 3
mm wheal diameter) or with known tendency for dermatographic urticaria.
8. Patients currently under allergen immunotherapy treatment or with a history of
immunotherapy treatment within the last 5 years to the extract to be tested in this study
Locations and Contacts
Bryan Martin, DO, Phone: 614-2934975, Email: bryan.martin@osumc.edu
Martha Morehouse Medical Plaza, 2050 Kenny Rd,Suite 2200 and Suite 2600, Columbus, Ohio 43221, United States; Recruiting Bryan Martin, DO, Principal Investigator
Additional Information
Starting date: March 2013
Last updated: November 15, 2013
|